Page 290«..1020..289290291292..300310..»

Analyzing Kiromic BioPharma (NASDAQ:KRBP) and LogicBio Therapeutics (NASDAQ:LOGC) – Defense World

Posted: August 14, 2022 at 1:59 am

LogicBio Therapeutics (NASDAQ:LOGC Get Rating) and Kiromic BioPharma (NASDAQ:KRBP Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

This table compares LogicBio Therapeutics and Kiromic BioPharmas net margins, return on equity and return on assets.

This table compares LogicBio Therapeutics and Kiromic BioPharmas top-line revenue, earnings per share (EPS) and valuation.

55.2% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 16.0% of Kiromic BioPharma shares are owned by institutional investors. 8.1% of LogicBio Therapeutics shares are owned by insiders. Comparatively, 3.5% of Kiromic BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

LogicBio Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of -0.27, indicating that its stock price is 127% less volatile than the S&P 500.

This is a summary of recent ratings and recommmendations for LogicBio Therapeutics and Kiromic BioPharma, as provided by MarketBeat.

LogicBio Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 1,513.16%. Given LogicBio Therapeutics higher probable upside, research analysts clearly believe LogicBio Therapeutics is more favorable than Kiromic BioPharma.

LogicBio Therapeutics beats Kiromic BioPharma on 7 of the 12 factors compared between the two stocks.

(Get Rating)

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

(Get Rating)

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Originally posted here:
Analyzing Kiromic BioPharma (NASDAQ:KRBP) and LogicBio Therapeutics (NASDAQ:LOGC) - Defense World

Posted in Genetic medicine | Comments Off on Analyzing Kiromic BioPharma (NASDAQ:KRBP) and LogicBio Therapeutics (NASDAQ:LOGC) – Defense World

PVM to Play Role in Research on New Patent-pending Method to Mass-produce Antitumor Cells to Treat Blood Diseases and Cancer – Purdue University

Posted: August 14, 2022 at 1:59 am

Friday, August 12, 2022

A Purdue University chemical engineer has improved upon traditional methods to produce off-the-shelf human immune cells that show strong antitumor activity, according to a paper published in the peer-reviewed journal Cell Reports. And future research plans include clinical trials involving the Purdue University College of Veterinary Medicine.

Dr. Xiaoping Bao, a Purdue University assistant professor in the Davidson School of Chemical Engineering, said CAR-neutrophils, or chimeric antigen receptor neutrophils, and engraftable HSCs, or hematopoietic stem cells, are effective types of therapies for blood diseases and cancer. Neutrophils are the most abundant white cell blood type and effectively cross physiological barriers to infiltrate solid tumors. HSCs are specific progenitor cells that will replenish all blood lineages, including neutrophils, throughout life.

These cells are not readily available for broad clinical or research use because of the difficulty to expand ex vivo to a sufficient number required for infusion after isolation from donors, Dr. Bao said. Primary neutrophils especially are resistant to genetic modification and have a short half-life.

Dr. Bao has developed a patent-pending method to mass-produce CAR-neutrophils from human pluripotent stem cells (hPSCs), that is, cells that self-renew and are able to become any type of human cell. The chimeric antigen receptor constructs were engineered to express on the surface of the hPSCs, which were directed into functional CAR-neutrophils through a novel, chemically defined protocol.

The method was created in collaboration with Dr. Qing Deng in Purdues Department of Biological Sciences; Dr. Hal E. Broxmeyer, now deceased, at the Indiana University School of Medicine; and Dr. Xiaojun Lian at Pennsylvania State University.

We developed a robust protocol for massive production of de novo neutrophils from human pluripotent stem cells, Dr. Bao said. These hPSC-derived neutrophils displayed superior and specific antitumor activities against glioblastoma after engineering with chimeric antigen receptors.

Dr. Bao disclosed the innovation to the Purdue Research Foundation Office of Technology Commercialization, which has applied for an international patent under the Patent Cooperation Treaty system of the World Intellectual Property Organization. The innovation has been optioned to an Indiana-headquartered life sciences company.

We will also work with Dr. Timothy Bentley and his team at the Purdue College of Veterinary Medicine to run clinical trials in pet dogs with spontaneous glioma, Dr. Bao explained. Dr. Bentley is professor of neurology and neurosurgery in the College of Veterinary Medicines Department of Veterinary Clinical Sciences.

This research project was partially supported by the Davidson School of Chemical Engineering and College of Engineering Startup Funds, Purdue Center for Cancer Research, Showalter Research Trust and federal grants from the National Science Foundation and National Institute of General Medical Sciences.

Click here to view a complete news release.

Writer(s): Steve Martin | pvmnews@purdue.edu

Read more:
PVM to Play Role in Research on New Patent-pending Method to Mass-produce Antitumor Cells to Treat Blood Diseases and Cancer - Purdue University

Posted in Genetic medicine | Comments Off on PVM to Play Role in Research on New Patent-pending Method to Mass-produce Antitumor Cells to Treat Blood Diseases and Cancer – Purdue University

Corporate America’s Abortion Radicalism – The American Conservative

Posted: August 14, 2022 at 1:59 am

Pharmaceutical giant Eli Lilly and Co. is reportedly considering leaving Indiana as the Hoosier state has decided to go forward with more abortion restrictions.

Lilly recognizes that abortion is a divisive and deeply personal issue with no clear consensus among the citizens of Indiana, the company said in a statement Saturday. Despite this lack of agreement, Indiana has opted to quickly adopt one of the most restrictive anti-abortion laws in the United States.

Given Eli Lillys statement, you might think Indianas new abortion ban would be one of the toughest in the country, in line with other states like South Carolina, which is considering a near-total ban with exceptions only if the life of the mother is in danger. But Indianas new abortion ban thats slated to take effect on Sept. 15 only restricts abortions after ten weeks. It includes carve outs to protect the life of the mother, and continues to allow abortions in the case of rape and incest. The Indiana legislature, however, decided not to go forward with a provision that would require women who get abortions under the rape and incest exemptions to sign a notarized affidavit of their claim.

Indianas new pro-life law would also require that abortions be performed in hospitals or outpatient centers owned by hospitals, which means all abortion clinics will lose their licenses and, thankfully, be forced out of the state. Doctors who perform illegal abortions or fail to file proper reports about the procedure will also lose their medical licenses.

"We are concerned that this law will hinder Lilly's and Indiana's ability to attract diverse scientific, engineering and business talent from around the world, Eli Lillys statement continued. While we have expanded our employee health plan coverage to include travel for reproductive services unavailable locally, that may not be enough for some current and potential employees."

Read that again, and let it sink in. One of the most powerful companies in the world is openly pledging to circumvent the abortion laws in its home state by pledging to help women travel elsewhere to get abortions on the companys dime. All in the name of ensuring that the killing of unborn babies continues unabated.

Eli Lilly has made quite the habit of going after kids. In one of the largest settlements in pharmaceutical-industry history, Eli Lilly had to pay out $1.42 billion after it pleaded guilty to pushing Zyprexa, an antipsychotic, for off-label uses in children and elderly dementia patients in 2009.

Eli Lilly is the second- or third-largest employer in Indianapolis with 10,400 employees working out of its headquarters there.

"As a global company headquartered in Indianapolis for more than 145 years, we work hard to retain and attract thousands of people who are important drivers of our states economy. Given this new law, we will be forced to plan for more employment growth outside our home state, the Eli Lilly statement went on to say.

To a certain extent, Eli Lillys shift away from its conservative home state of Indianapolis in favor of the blue coasts has been going on for some time. The pharmaceutical giant has research and development outfits in New York City, San Francisco, and San Diego. It also recently announced a $700 million building project for a genetic-medicine facility in Boston. Nevertheless, Eli Lillys willingness to throw away almost 150 years of history, and replace or force large swaths of their workforce to move in the name of making sure women can kill their unborn child in the womb is a testament to the corporate sectors left-wing radicalism.

For far too long, the conservative movement has been mystified at corporate Americas willingness to jump in bed with liberals. Liberals want to raise taxes and regulate the economy, conservatives thought. How could corporate America side with them? Initially, conservatives thought it was an aberration. Then conservatives started to talk about betrayal. But for a while, the strongest language we could muster in response was that these institutions have been hijacked by low-level millennials.

Surely, theres a bit of truth to the "hijacked" narrative. But the alliance between liberals and capital is much more fundamental. By encouraging the individual's pursuit of the unbounded self, liberalism severs the ties that bind individuals to people and place. Marriage, family, community, and nation must all be radically redefined as nothing more than non-binding contracts the individual defines for himself.

But man, Plato reminds us, is a being in search of meaning. Trying to purge these traditional institutions of meaning does not not rid us of our natural impulse to pursue it. Whats left, then, to provide meaning, if life is but a series of self-conceived nugatory contracts?

In these circumstances, capitalism has an answer. If life is nothing but a series of contracts, then at least you get monetarily compensated for selling your labor, which cant be said for arguably more difficult jobs, being a husband or a wife or a parent.

Subscribe Today Get weekly emails in your inbox

Corporate Americas support for abortion isnt just a matter of protecting its bottom line. Liberalism and capitalism are natural allies because both seek to free the individual from natural constraints, the former through rights, the latter through the pursuit of profit.

No surprise, Eli Lilly found some support from the Indianapolis Chamber of Commerce. "Over the last two weeks, the Indiana General Assembly has debated a substantial policy change on the issue of abortion in a compressed timeframe," a statement from the chamber said. "Such an expedited legislative process rushing to advance state policy on broad, complex issues is, at best, detrimental to Hoosiers, and at worst, reckless."

This isnt to say that conservatives shouldnt care about free and fair markets. Its the recognition that markets, like the rights that we enjoy while participating in them, are intermediate ends to a higher social goodthe flourishing of human society. And babies, dare I say, are pretty important to that mission.

Go here to read the rest:
Corporate America's Abortion Radicalism - The American Conservative

Posted in Genetic medicine | Comments Off on Corporate America’s Abortion Radicalism – The American Conservative

A team of Oxford and Mexican researchers want to diversify genomic databases. Can they end ‘parachute science,’ too? – STAT

Posted: August 14, 2022 at 1:59 am

MEXICO CITY Back in 2019, while she worked for the biotech Regeneron Pharmaceuticals, Claudia Gonzaga heard a rumor that thrilled her. The company would begin sequencing and analyzing the DNA of 150,000 people from Mexico City, thanks to a research collaboration with the University of Oxford.

As the only Mexican geneticist at Regeneron, Gonzaga saw this as a unique opportunity. She had previously tried to convince her colleagues to sequence the genomes of people from Mexico, where researchers have found a stunning amount of human genetic diversity, but to no avail. The new partnership meant she would be able to resume her plans. I was so pleased, she said.

She was similarly surprised when she later learned that Oxford researchers had very much tried to keep this a Mexican study. While Oxford, not a Mexican institution, had physical custody of all the samples, Mexican epidemiologists had actively participated in almost every step of the research, and once the genetic data were ready, the Oxford team would make them public and offer rapid, free, and preferential access to Mexican scientists.

advertisement

It went against the long history of parachute science or helicopter research when researchers from wealthier nations visit low- and middle-income countries to collect data and samples, analyze them back at home, and publish the results with little or no involvement of local scientists.

Gonzaga left the company for academia in 2020 and went back to Mexico. She hasnt gotten her hands on the data yet, though shes already planning what shell do with them, such as hunting for genetic variants closely linked to diseases like breast cancer and calculating how frequent they are in Mexicans. And she is pushing to have a physical copy of the genetic biobank hosted at her institution.

advertisement

I have many ideas of things we can do, said Gonzaga, now a genomicist studying genetic disorders at the International Laboratory for Human Genome Research of the National Autonomous University of Mexico (UNAM) in Quertaro. What I need now is having access to the data.

The building and study of massive sets of genetic data from Mexicans is part of a global effort to make genetic collections and biobanks, which are still too white, representative of all humans. Though necessary to achieve that goal, international partnerships pose uncomfortable questions, such as who owns the data, whom to share it with, and what for.

Experts mostly laud the Mexico City project for avoiding the worst sins of parachute science and aiming to strengthen research capacity in the country, though Oxford controls access to the data and Mexican scientists like Gonzaga are still waiting for it. Some experts also warn that, when trying to promote fairer international collaborations and diversify the people they study, local researchers must be careful not to perpetuate the same discrimination they sometimes face, by excluding Mexicos many Indigenous populations from participating actively in research involving their communities.

Lets not forget that exploitation, extractivism, and colonialism also exist [in our countries], said Amaranta Manrique de Lara, a genomicist and bioethicist at the General Hospital of Mexico in Mexico City. In our effort to combat old biases, we may be generating new ones.

In the 1990s, a simple yet ambitious question arose: What is killing Mexicans?

We knew an awful lot about what killed white middle-aged men and women, said Jonathan Emberson, a statistical epidemiologist at the University of Oxford. But there was a real dearth of evidence for everyone else, he added.

To find that data, a group of epidemiologists from Oxford and Mexicos Secretariat of Health teamed up. Between 1998 and 2004, they sent hundreds of trained nurses to the homes of more than 150,000 people in two contiguous districts in Mexico City Iztapalapa and Coyoacn to ask about their health history, measure their vitals, and draw a tube of blood from them. But their blood samples, and the DNA within them, remained largely untouched for about two decades at Oxford. Until 2019, that is, when the team approached Regeneron and the pharmaceutical companies AstraZeneca and AbbVie for help with sequencing and analyzing the genetic material.

It was then that Gonzaga first heard about the Mexico City Prospective Study, or MCPS an ongoing project that has followed participants over the years to understand the social, lifestyle, physical, and genetic causes of complex diseases, such as diabetes and obesity. The study resurveyed 10,000 surviving participants between 2015 and 2019.

It really is a waiting game, said Emberson, who is the program leader for the MCPS. You need to wait until, sadly, enough participants have had diseases of interest and you dont get that within just a few years.

In fact, it was not until 2016 that the MCPS published its first major finding. After reviewing the death certificates of participants, the researchers found that those with diabetes had a strikingly worse prognosis than that seen in high-income nations. In Mexico City, it turns out, the rate of death from any cause was almost four times as high among people with diabetes as among those without the disease.

More recently, in a preprint published in late June, the team added to its extensive evidence the genetic sequences for MCPS participants, hoping to find new gene variants associated with diseases. They mostly focused on the exomes, regions that make up the 2% of the human genome that code for proteins, which drug hunters typically mine to uncover disease-linked changes.

With this, the MCPS has become the most extensive genetic study in people outside the U.S., the U.K., or Iceland which together account for over 72% of all participants in genome-wide association studies, known as GWAS, which scientists use to hunt for snippets of DNA that may be linked to a certain disease or trait. Latin Americans make up around 8% of all people on the planet, yet they constitute 0.25% of all these genetic studies, according to the online tracker GWAS Diversity Monitor.

The MCPS genetic sequences have already proven their worth. They were included in a paper, published in Science last year, that discovered rare mutations that inactivated a gene called GPR75, which was associated with protection against weight gain people with these variants tended to weigh about 12 pounds less and face a 54% lower risk of obesity than those without the mutation. (Emberson noted that while MCPS data were a worthwhile addition to the GPR75 paper, the discovery didnt ultimately depend on any of it. Regeneron spokesperson Ella Campbell, however, wrote in an email to STAT that they were needed to ensure the discovery held true with different populations.)

Regeneron and AstraZeneca have announced they are developing drug candidates directed against GPR75 to treat obesity. Should a medicine eventually reach market, Campbell wrote, Oxford and Regeneron would be able to share or generate their own intellectual property, according to their collaboration agreement.

As the only Mexican institution in the MCPS, UNAM equally shares any intellectual property rights with Oxford. We both own the information, said Jess Alegre Daz, a medical epidemiologist at UNAMs Faculty of Medicine in Mexico City and one of the three Mexican principal investigators involved in the MCPS. Were Mexicans studying Mexicans.

Elida Fernndez, a lawyer at UNAM, said a research agreement between both universities was signed in early August with the purpose of resurveying surviving participants. Among other things, the contract, which STAT reviewed, dictates that both UNAM and Oxford can use the samples and data and that the results of the research including all intellectual property rights, data, discoveries, and patents will be shared between both institutions.

The vast amount of genetic data pouring out of the MCPS has some Mexican geneticists salivating to get their hands on it.

In 2016, Andrs Moreno Estrada, a human population geneticist at Mexicos National Laboratory of Genomics for Biodiversity in Irapuato, and colleagues launched the MX Biobank project, which sequenced the DNA of about 6,000 people from across the country, including many from Indigenous communities and rural areas. Though the biobank also works in partnership with Oxford, Moreno Estrada said that they negotiated to keep the guts of the project in Mexico to build its research capacity the samples are hosted in a Mexican institution, the bulk of the genomic analysis is led by the Mexican research team, and many of the projects former students are continuing their careers studying the data they generated.

He recently approached the MCPS researchers in hopes to collaborate and share their respective datasets with each other. We dont have their numbers, he said, referring to the size of the MCPS dataset. They are discovering things that we cant.

He might need to wait a bit longer.

Regeneron has launched an online browser that includes the genetic variation found across all 150,000 participants, making it freely accessible to anyone. But the browser, for now, is not very useful, said Gonzaga. It lacks key information that makes it difficult to know whether a disease-linked variant is present in 100 or 10,000 people, for example.

So far, the MCPS research group at Oxford holds the custody of the studys samples and data. It happens to be that this process has been managed at Oxford at the moment, Emberson said. But, I mean, maybe in the future it will be done separately or jointly with UNAM. The recently signed agreement may allow that.

Still, the MCPS has made important progress to support Mexican scientists and strengthen local research capacity. Oxford has trained staff in Mexico and paid for courses and short-term research placements, said Emberson. And as soon as the data are clean, Mexican researchers will have free and preferential access to it for a period of two years. Researchers based elsewhere in the world will need to pay up to 2,500 (about $3,000) to receive the data.

The policy feels like a step in the right direction, said Mashaal Sohail, an evolutionary geneticist at UNAMs Center for Genomic Sciences in Cuernavaca. And one thats not very common. Even within Mexico, she said, people are generating data and not sharing it with other academic groups.

Even if international partnerships move toward fairer conditions, some scientists warn that may not be enough.

Stripping [genomic science] of its colonialism, hierarchy, and structural violence has to be an everyday task, said Jocelyn Che Santiago, a Binniz genomic scientist at UNAM in Mexico City (the Binniz, also known as Zapotec, are one of Mexicos 68 Indigenous groups.) If we are not going to discuss the colonialism [aspect] of our research, then whats the point?

For decades, Mexico has tried to guard the genetic data of its citizens. In 2008, Congress passed a national law that embraced the idea of genomic sovereignty, a concept that aims to protect Mexican DNA by itself absurdly difficult to define, critics say from foreign interests. And many researchers saw it as a way to break this relationship between us Mexicans as suppliers of samples, and foreign scientists as the ones who analyzed [them], said Ernesto Schwartz-Marn, an ethnographer who probes the interaction between race and genomics at the University of Exeter, U.K.

But the law has made little difference. Genomic sovereignty is a bulls term, Schwartz-Marn said. Its impossible to execute because theres no way to say what the Mexican genome is or looks like. And theres no consensus about who is supposed to guard it.

In 2010, the state of Nayarit included a provision in its constitution on genomic sovereignty. Schwartz-Marn indirectly participated in its design, and suggested that the language enable Indigenous peoples to protect their own genetic data. When we tried to get this into the draft, he said, thats exactly what [legislators] erased.

The incident is a window into a double standard in Mexico, said Manrique de Lara. When studying Indigenous populations or other groups, such as people who live with a disability or disease, Mexican scientists often do a lot of this parachute research we so often criticize. And rare is the case when study participants see any benefits from the science, she added.

The way to counter that is by creating fairer collaborations, Che Santiago said, where participants have an active role in the research such as deciding what questions to ask, how to ask them, and who has custody over the data. That we are no longer part of the menu, she said, but part of the table where decisions are made.

Its something thats happening elsewhere. In Australia, the National Centre for Indigenous Genomics is governed by a majority-Indigenous board, and has approached communities to ask what they wish to do with their samples. In Chile, recent efforts to explain the uses and limitations of genetics led scientists and Indigenous people to come together in a three-day workshop. And in countries like the U.S. and Canada, the Summer Internship for Indigenous peoples in Genomics (also known as SING) have trained Indigenous participants in genomics and its ethical implications.

Such changes are coming slowly in Mexico. Manrique de Lara and colleagues who teach future geneticists at UNAMs Center for Genomic Sciences have started to incorporate parachute science, scientific colonialism, and other bad practices into the syllabus of their classes.

If we do our job right, she said, well be seeing this internal change in the next generation of researchers.

Correction: This story has been updated to say that the MCPS has become the most extensive genetic study in people outside the U.S., the U.K., or Iceland.

Read this article:
A team of Oxford and Mexican researchers want to diversify genomic databases. Can they end 'parachute science,' too? - STAT

Posted in Genetic medicine | Comments Off on A team of Oxford and Mexican researchers want to diversify genomic databases. Can they end ‘parachute science,’ too? – STAT

The aging heart accumulates mutations while losing the ability to repair them – EurekAlert

Posted: August 14, 2022 at 1:59 am

Why does the risk of heart disease go up as we age? Known risk factors such as hypertension or high cholesterol dont explain all cases. A first-of-its-kind study from Boston Childrens Hospital now shows that the cells that make up our heart muscle accumulate new genetic mutations over time whilelosing the ability to repair them.

Findings were published August 11 in the journal Nature Aging.

The research team, led by Sangita Choudhury, PhD, and August Yue Huang, PhD, in the Division of Genetics and Genomics at Boston Childrens, sequenced the entire genomes of 56 individual heart muscle cells, known as cardiomyocytes, from 12 people across the age spectrum from infancy to 82 years who had died from causes unrelated to heart disease.

Cataloguing mutations in the aging heart

Using sophisticated bioinformatics techniques and analyses, the team compared the number of non-inherited mutations, known as somatic mutations, in cells of different ages and also looked for mutational patterns or signatures that might illuminate the mechanisms of heart disease.

This is the first time somatic mutations have been looked at in the human heart at the single-cell level, says Choudhury, who is co-first author on the paper with Huang.

The older the cells were, the more single letter changes (known as single-nucleotide variants) they had in their DNA. The pattern of these mutations suggested that many of them were caused by oxidative damage.

Because the heart is always pumping, it uses a lot of energy, elaborates Ming Hui Chen, MD, MMSc, a cardiologist in the Division of Genetics and Genomics and Department of Cardiology at Boston Childrens. This energy production creates chemical byproducts known as reactive oxygen species or ROS. When levels of ROS get too high, they can damage DNA.

Adding insult to injury, mutations also affected pathways cells normally use to repair DNA damage. The mechanisms that repair DNA damage are also impacted by age, says Choudhury. These may be overwhelmed if there is enough oxidative damage.

The technically difficult study drew on single-cell whole genome sequencing and bioinformatics techniques pioneered in the laboratory of Christopher Walsh, MD, PhD, at Boston Childrens, of which Choudhury and Huang are members. The Walsh lab recently used the methods to document the accumulation of mutations in neurons in people with Alzheimers disease.

Typically, cells that dont continue to divide, like heart cells, are less susceptible to mutations. But the researchers found that cardiomyocytes accumulated mutations as fast or faster than some dividing cell types; the researchers calculated that they averaged more than 100 new mutations per year per cell.

Heart cells also accumulated mutations at rate three times faster than neurons, another cell type that doesnt divide, says Huang.

In addition to DNA repair pathways, mutations affected genes involved in the cytoskeleton, the scaffolding that gives cells their structure, and other basic cell functions.

As you age and get more mutations, youre adding deleterious effects that might push the heart past a tipping point into disease, says Chen, who was co-senior investigator on the study with Walsh and Eunjung Alice Lee, PhD. It may get to a point where so much DNA is damaged that the heart can no longer beat well.

More to explore

The researchers note that their study only looked for single-nucleotide variants and did not investigate other types of mutations, such as DNA insertions or deletions. Also, because they looked at healthy heart cells, they cant establish that the mutations are involved in heart disease. In the future, they plan to look at mutations in tissue from patients with different cardiovascular diseases.

Chen, who studies how chest radiation and chemotherapy for cancer affects cardiac health, plans to collect data from cancer patients who have heart disease.

We also want to look at different cell types in the heart, adds Choudhury. Weve only touched the tip of the iceberg.

The study was funded by the American Heart Association, the National Heart, Lung and Blood Institute (R01HL152063), the Manton Center for Orphan Disease Research at Boston Childrens Hospital, the Allen Discovery Center for Human Brain Evolution, the Howard Hughes Medical Institute, the National Institute of Neurological Disorders and Stroke (R01NS032457), the National Institutes of Health (DP2AG072437; R01AG070921, K08AG065502, T32HL007627), the National Institute of General Medical Sciences (T32GM007753), the National Library of Medicine (T15LM007092), the Brigham and Womens Hospital Program for Interdisciplinary Neuroscience (via Lawrence and Tiina Rand), the BrightFocus Foundation (A20201292F), and the Doris Duke Charitable Foundation (2021183). The authors declare no competing interests.

About Boston Childrens Hospital

Boston Childrens Hospitalis ranked the#1 childrens hospitalin the nation byU.S. News & World Reportand is a pediatric teaching affiliate of Harvard Medical School. Home to the worlds largest research enterprise based at a pediatric medical center, its discoveries have benefited both children and adults since 1869. Today, 3,000 researchers and scientific staff, including 11members of the National Academy of Sciences,25 members of the National Academy of Medicine and10Howard Hughes Medical Investigators comprise Boston Childrens research community. Founded as a 20-bed hospital for children, Boston Childrens is now a 485-bed comprehensive center for pediatric and adolescent health care. For more, visit our Answers blogand follow us on social media @BostonChildrens, @BCH_Innovation, Facebook and YouTube.

- ### -

The authors declare no competing interests.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the original:
The aging heart accumulates mutations while losing the ability to repair them - EurekAlert

Posted in Genetic medicine | Comments Off on The aging heart accumulates mutations while losing the ability to repair them – EurekAlert

Senate Passes ‘Inflation Reduction Act’ Which Will Likely Make Inflation Worse – Reason

Posted: August 14, 2022 at 1:56 am

The U.S. Senate passed the misleadingly named Inflation Reduction Act on Sunday before senators adjourned until September. The billwhich allocates around $740 billionpassed with a tie-breaking vote from Vice President Kamala Harris; it will now head to the House of Representatives, which is expected to vote on it Friday.

Democrats say the bill will curb inflation by lowering energy and health care costs for some Americans. But inflationwhich is now impacting prices across the U.S. economy isn't actually reduced just because the government artificially lowers the consumer cost of a few items. And whether it will even succeed in bringing down things like health care costs is questionable.

An analysis by the nonpartisan Congressional Budget Office says the law will have a "negligible" effect on inflation. And more government spending will only make inflation worse in the long run: 230 economists have signed an open letter saying the proposed law will "perpetuate the same fiscal policy errors that have helped precipitate the current troubling economic climate."

"If we want to stop inflation, then the federal government needs to stop excessive spending, and the Federal Reserve needs to stop excessive money creation," tweeted former Rep. Justin Amash (LMich.). "Price controls and subsidies cannot stop or reduce inflation, but they will further harm the economy and make people poorer."

The behemoth bill is full of questionable spending, including $80 billion in increased funding for the IRS. Democrats say more money will mean that the tax agency can focus more of its auditswhich currently disproportionately burden low-income taxpayerson very wealthy Americans. Republicans reply this is spin, and that giving the IRS more money will mean it spends more time snooping on and auditing everyone.

The IRS "is an agency that only succeeded in answering about one out of every 50 phone calls during the 2021 tax season," Sen. John Thune (RS.D.) said last week on the Senate floor. "Yet 4 percent of the $80 billion is going to taxpayer services; 57 percent goes to enforcement, so that the IRS can spend more time harassing taxpayers around this country."

Thune and other Republicansalong with Arizona Democrat Kirsten Sinemaalso objected to a 15 percent corporate minimum tax rate for businesses making more than $1 billion in income annually. (Democrats say this part of the bill will bring in more than $300 billion in revenue for the government.) The Republicans and Sinema succeeded in getting an exemption for some businesses owned by private equity.

The bill contains many components of this administration's previous spending plans. It includes $300 billion for energy- and climate-related programs, and it creates tax credits for individuals buying electric vehicles or making energy efficient home improvements. It extends Affordable Care Act subsidies and introduces a $35 per month price cap on insulin for Medicare recipients.

But it's also missing many items on Democrats' wish list, including funding for child care programsand paid family leave, an extension of the child tax credit, and a cap on insulin prices for private insurance plans.

The package "was far smaller than the party's original $3.5 trillion vision, but larger than the slim health care legislation that lawmakers were considering just two weeks ago," notes Politico. "It's probably the last big party-line bill Democrats will be able to deliver for years, with the House expected to flip to Republicans in the November elections."

A heartbreaking story in The Atlantic looks at forced migrant family separations. These were, it shows, an explicit strategy, no matter how much the Trump administration asserted otherwise. "Separating children was not just a side effect, but the intent," writes Caitlin Dickerson. "Instead of working to reunify families after parents were prosecuted, officials worked to keep them apart for longer."

Indiana has passed an abortion banthat starts at conception.

Madison County, North Carolina, is putting AR-15s in all of its schools.

"Artificial eggs created using skin cells, sperm generated from implanted stem cells, and synthetic embryos are all recent breakthroughs made by different teams of researchers in the field of reproductive science," reports Reason's Ron Bailey. "All of these advances took place in mice, but the researchers believe that their findings can eventually be applied to human reproduction."

Here is the original post:
Senate Passes 'Inflation Reduction Act' Which Will Likely Make Inflation Worse - Reason

Posted in Arizona Stem Cells | Comments Off on Senate Passes ‘Inflation Reduction Act’ Which Will Likely Make Inflation Worse – Reason

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 – Business Wire

Posted: August 14, 2022 at 1:54 am

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525).

We are excited to further advance the development of GDA-201, a NAM-enabled natural killer (NK) cell therapy candidate which we believe has the potential to be a new readily available, cryopreserved treatment option for cancer patients with relapsed/refractory lymphoma, said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell. Our NK cells elicited an adaptive immune response in patients in the previous investigator-sponsored study with the fresh formulation of GDA-201, potentially leading to durable remissions. We are truly grateful for the contribution of all the participants and clinical collaborators who will allow us to continue studying GDA-201 in this multi-center open label trial.

The Phase 1 portion of the study is a dose escalation phase, designed to evaluate the safety of GDA-201, and will include patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL)/high grade B-cell lymphoma, marginal zone lymphoma or mantle cell lymphoma. The Phase 2 expansion phase is designed to evaluate the safety and efficacy of GDA-201 in 63 patients comprised of two cohorts of patients with either FL or DLBCL. The study will include patients who have relapsed or refractory lymphoma after at least two prior treatments, which may include CAR-T or stem cell transplant.

Interest in NK cell therapies has increased in recent years as a potential alternative to current cell therapies, as NK cells have the potential to be effective in hematological and solid tumors while avoiding common safety issues, said Veronika Bachanova, M.D., Ph.D., University of Minnesota. We are particularly excited about Gamidas cryopreserved formulation of GDA-201, which has potential as a new treatment option for patients.

GDA-201 leverages Gamida Cells proprietary NAM (nicotinamide) technology platform to expand the number and functionality of NK cells to direct tumor cell killing properties and antibody-dependent cellular cytotoxicity (ADCC). In an investigator-sponsored Phase 1/2 study in patients with relapsed or refractory lymphoma, treatment with the fresh formulation of GDA-201 with rituximab demonstrated significant clinical activity. Of the 19 patients with non-Hodgkin lymphoma (NHL), 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate of 68%. Two-year data on outcomes and cytokine biomarkers associated with survival data demonstrated a median duration of response of 16 months (range 5-36 months) and an overall survival at two years of 78% (95% CI, 51%91%). In this study, GDA-201 was well-tolerated and no dose-limiting toxicities were observed in 19 patients with NHL and 16 patients with multiple myeloma. The most common Grade 3/4 adverse events were thrombocytopenia, hypertension, neutropenia, febrile neutropenia, and anemia. There were no incidents of cytokine release syndrome, neurotoxic events, graft versus host disease or marrow aplasia.

About NAM Technology

Our NAM-enabled technology, supported by positive Phase 3 data for omidubicel, is designed to enhance the number and functionality of targeted cells, enabling us to pursue a curative approach that moves beyond what is possible with existing therapies. Leveraging the unique properties of NAM, we can expand and metabolically modulate multiple cell types including stem cells and NK cells with appropriate growth factors to maintain the cells active phenotype and enhance potency. Additionally, our NAM technology improves the metabolic fitness of cells, allowing for continued activity throughout the expansion process.

About GDA-201

Gamida Cell applied the capabilities of its NAM-enabled cell expansion technology to develop GDA-201, an innate NK cell immunotherapy candidate for the treatment of hematologic and solid tumors in combination with standard-of-care antibody therapies. GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical trial results. GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs. Furthermore, GDA-201 improves ADCC and tumor targeting of NK cells. There are approximately 40,000 patients with relapsed/refractory lymphoma in the US and EU, which is the patient population that will be studied in the currently ongoing GDA-201 Phase 1/2 clinical trial.

For more information about GDA-201, please visit https://www.gamida-cell.com. For more information on the Phase 1/2 clinical trial of GDA-201, please visit http://www.clinicaltrials.gov.

GDA-201 is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.

About Gamida Cell

Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapy candidates with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit http://www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to: the timing of initiation of the expansion portion of the currently ongoing Phase 1/2 clinical trial of GDA-201, as well as the progress of, and data reported from, this clinical trial; the potentially life-saving or curative therapeutic and commercial potential of Gamida Cells product candidates (including omidubicel and GDA-201); and Gamida Cells expectations for the expected clinical development milestones set forth herein. Any statement describing Gamida Cells goals, expectations, or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including statements related to: the impact that the COVID-19 pandemic could have on our business; the scope, progress and expansion of Gamida Cells clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics; and the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cells Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on May 12, 2022, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cells actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

Follow this link:
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 - Business Wire

Posted in Minnesota Stem Cells | Comments Off on Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 – Business Wire

About Regenerative Medicine – Center for Regenerative Medicine – Mayo …

Posted: August 14, 2022 at 1:52 am

Andre Terzic, M.D., Ph.D.

Center for Regenerative Medicine, Mayo Clinic

Andre Terzic, M.D., Ph.D.: Regenerative medicine is an exciting component of modern health care. It harnesses breakthroughs in technologies to address major unmet needs of the population, both nationally but also globally. With the successes of traditional medicine, we'll live longer. And aging has been viewed as a major triumph of humanity. At the same time, unfortunately, with aging, we are facing with a growing pandemic of so-called chronic diseases diseases that live with us throughout our lifespan, heart disease, cancer, diabetes and so on.

So regenerative medicine comes with this new ability to understand how our body can heal and to harness its innate ability, that self-ability to heal, to actually provide new solutions to these patients in need. So the Center for Regenerative Medicine at Mayo Clinic has been built to address the unmet needs of patients. It builds on our new knowledge, bringing new ways to promote the self-repair ability of our body.

There have been magic moments during these few decades that we have built the regenerative medicine field. One such moment was when we saw, for the first time, how out of a stem cell, we can create new beating heart tissue. It was a revolution for us.

We would like to bring now this knowledge that may have started in one field to build it across fields as the new science allows, essentially, for learning between fields. We need true, radical innovation to move the current knowledge into new solutions. That is where regenerative medicine has a unique role. It changes the way we treat patients.

Excerpt from:
About Regenerative Medicine - Center for Regenerative Medicine - Mayo ...

Posted in Regenerative Medicine | Comments Off on About Regenerative Medicine – Center for Regenerative Medicine – Mayo …

The Alliance for Regenerative Medicine Announces the Appointment of Timothy D. Hunt as Chief Executive Officer – GlobeNewswire

Posted: August 14, 2022 at 1:52 am

The Alliance for Regenerative Medicine Announces the Appointment of Timothy D. Hunt as Chief Executive Officer

WASHINGTON, D.C. August 10, 2022

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy sector, today formally announced that its Board of Directors has appointed Timothy D. Hunt as the organizations next Chief Executive Officer. Hunt will succeed Janet Lynch Lambert, who announced in April her plan to step down as CEO and who served on the Boards Search Committee. Hunt will start at ARM on September 6.

We are excited to welcome Tim to the ARM team at such a pivotal moment for our sector, said Emile Nuwaysir, Chair of the ARM Board and Search Committee,and President and Chief Executive Officer of Ensoma, an in vivo genomic medicines company. Tims two decades of experience advocating for biotechnology companies, knowledge of the key issues facing the cell and gene therapy field, and expertise in leading teams make him the ideal choice to guide ARM in building the future of medicine. Tim has a deep philosophy of engagement with major stakeholders that will support ARM members and help bring cell and gene therapies into mainstream medical practice.

Hunt was most recently the Chief Culture and Corporate Affairs Officer at Xilio Therapeutics, a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer. Prior to that, he was the Chief Corporate Affairs Officer at CRISPR gene-editing pioneer Editas Medicine, where he led the companys global policy and government affairs, bioethics, communications, market development and human resources initiatives. He also served in executive public affairs roles at Cubist Pharmaceuticals and Biogen.

Hunt was an Advisory Group member of the Value-Based Payments for Medical Products consortium at the Duke-Margolis Center for Health Policy. He also has been a member of the Board of Directors of the non-profit organization Life Science Cares and has chaired the Ethics Committee of the American Society of Gene and Cell Therapy (ASGCT). Hunt previously served as a member of ARMs Gene Editing Task Force and on the Biotechnology Innovation Organizations Gene Editing Working Group. He received a B.A. in history and philosophy from Boston College and a J.D. from the Columbus School of Law at the Catholic University of America.

I am honored to succeed Janet as Chief Executive Officer of the Alliance for Regenerative Medicine and for the tremendous opportunity to build upon her legacy of developing ARM into the leading sector advocate and resource for the industry, said Hunt. Cell and gene therapies are already transforming patients lives, and we are on the cusp of even more breakthroughs in both rare and prevalent diseases. Our mission is both urgent and clear: to engage all our major stakeholders to ensure the patients we serve have access to the durable and potentially curative therapies of the present and future.

Tim is an excellent choice to continue to grow and strengthen this amazing organization and help realize the potential of regenerative medicine, said Lambert, whose tenure includes doubling ARMs global membership to 425 members, strengthening the organizations advocacy in the US and Europe, and building the ARM team.

Cell and gene therapies to treat blood cancers, spinal muscular atrophy, and an inherited form of blindness are approved in the US and Europe. 2022 could be a record year for new gene therapy approvals for rare disease, and regulators in the US and Europe could approve the first such therapies for hemophilia and sickle cell disease in late 2022 and 2023. More than 2,400 regenerative medicine clinical trials 60% of which targeted prevalent diseases including diabetes and cardiovascular disease were active globally at the end of 2021. ARM is committed to working with stakeholders to ensure that patients benefit from this rapidly advancing pipeline of transformative therapies.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organisation dedicated to realizing the promise of advanced therapy medicinal products (ATMPs).ARMpromotes legislative, regulatory, reimbursement and manufacturing initiativesin Europe and internationally to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-engineered therapies.Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing ATMPs.In its 12-year history,ARMhas become the global voice of the sector, representing the interests of 425+ members worldwide and 80+ members across 15 Europeancountries, including small and large companies, academic research institutions, major medical centres and patient groups.To learn more aboutARMor to become a member, visithttp://www.alliancerm.org.

Media inquiries

For more information or for media requests, please contact Stephen Majors, Senior Director of Public Affairs for ARM, atsmajors@alliancerm.org.

Original post:
The Alliance for Regenerative Medicine Announces the Appointment of Timothy D. Hunt as Chief Executive Officer - GlobeNewswire

Posted in Regenerative Medicine | Comments Off on The Alliance for Regenerative Medicine Announces the Appointment of Timothy D. Hunt as Chief Executive Officer – GlobeNewswire

FDA Issues Draft Guidance to Facilitate Development of Human Gene Therapy, CAR T Cell, and Regenerative Medicine Products – Wilson Sonsini Goodrich…

Posted: August 14, 2022 at 1:52 am

The Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) updated its Guidance Agenda in June 2022,1which provides that the agency plans to issue 18 guidance documents in 2022, including eight guidance documents on tissues and advanced therapies. In this alert, we highlight some key considerations from three draft guidance documents on human gene therapy products that incorporate gene editing (GE) components, chimeric antigen receptor (CAR) T cell products, and regenerative medicine therapies that can benefit biopharmaceutical developers and sponsors. Recognizing the challenges of developing such complex, multi-component biologic drug products, including unanticipated risks associated with on-target and off-target activities, these draft guidance documents describe the FDA's recommendations for preclinical and clinical testing, chemistry, manufacturing, and controls (CMC), as well as information that should be included in investigational new drug (IND) applications to ensure proper identity, potency/strength, quality, and purity of the investigational drug products. FDA recommends sponsors of such complex products to communicate with the Office of Tissues and Advanced Therapies (OTAT) in CBER early in product development before submission of an IND, to discuss the product-specific considerations in preparation for transitioning to the clinical phase.

FDA expects detailed information and data IND applications before sponsors can transition to clinical testing. We recommend biopharmaceutical developers and sponsors review the applicable FDA draft guidance documents early in their product development process to identify these needs. Work closely with both FDA regulatory counsel and intellectual property/patent counsel to ensure there is sufficient data to support an IND application, including adequate testing and quality control measures, and that CMC, preclinical, and clinical development plans are coordinated with intellectual property and patent strategies to ensure robust protection of their intellectual property and to maximize the benefits of their patents and FDA regulatory exclusivities. We also encourage interested persons to submit comments to shape the policies proposed in FDA's draft guidance documents prior to finalization.

Draft Guidance for Industry: Human Gene Therapy Products Incorporating Genome Editing2

Draft Guidance for Industry: Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products3

Draft Guidance for Industry: Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies4

Stakeholders have until September 14, 2022, to submit comments to this draft guidance to ensure they are considered by FDA before finalization of the guidance.

For More Information

For questions regarding FDA strategy, approval, and regulatory compliance, please contact any member of Wilson Sonsini'sFDA regulatory, healthcare, and consumer productspractice. For questions regarding intellectual property and patent counseling, please contact any member of Wilson Sonsini'spatents and innovationspractice.

Andrea Chamblee,Paul Gadiock, andEva Yincontributed to the preparation of this Wilson Sonsini Alert.

[1] FDA, Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2022 (Updated June 2022), available at https://www.fda.gov/media/120341/download.

[2] FDA, Draft Guidance for Industry: Human Gene Therapy Products Incorporating Genome Editing (March 2022), available at https://www.fda.gov/media/156894/download.

[3] FDA, Draft Guidance for Industry: Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products, available at https://www.fda.gov/media/156896/download.

[4] FDA, Draft Guidance for Industry: Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies (June 2022), available at https://www.fda.gov/media/159237/download.

Read the original here:
FDA Issues Draft Guidance to Facilitate Development of Human Gene Therapy, CAR T Cell, and Regenerative Medicine Products - Wilson Sonsini Goodrich...

Posted in Regenerative Medicine | Comments Off on FDA Issues Draft Guidance to Facilitate Development of Human Gene Therapy, CAR T Cell, and Regenerative Medicine Products – Wilson Sonsini Goodrich…

Page 290«..1020..289290291292..300310..»